Paul Taylor

The FDA has extended its review of Capricor Therapeutics' Duchenne muscular dystrophy (DMD) drug candidate, deferring the decision while the agency

The 23-year-old only joined Forest last year in a €35million (£29.3m) move from Strasbourg.

Having set Metsera on its journey to a $10 billion takeover, Arch Venture Partners and Population Health Partners have powered their new startup—Sentivera—to a licensing deal worth up to $1.5 billion.

The National Advertising Division (NAD) has delivered a mixed verdict in a row over hair-loss ads, telling Hims & Hers Health to change certain claims while dismissing other challenges brought by Kenvue.

This is no longer 2023. By Paul Taylor |

Jonathan Pratt will take over the role on Sept. 1. The announcement ends Qiagen's nearly 10-month search for a new chief executive.

The Austrian head coach reflected on Forest's development after they lost 2-0 to Leeds United in the Carabao Cup second round.

For the second time in two years, Medtronic has pulled capsules from the market over a fault that could obstruct patients’ airways.

How the M's must wish for the previous roster expansion rules. By Paul Taylor |

Buckle up for a painful trip down memory lane. By Paul Taylor |